Navio Theragnostics, Inc.
Navio Theragnostics, Inc. empowers healthcare partners by engaging individuals as active contributors through a HIPAA and GDPR compliant platform that facilitates real-world data collection for clinical trials and studies. Navio offers a flexible, cost-effective interface for personalized engagement and supports a variety of research initiatives to improve cancer patient outcomes.
Navio Theragnostics Services
Navio Theragnostics, Inc. offers a real-world data collection platform designed for healthcare partners to engage individuals as active contributors. The platform supports rapid deployment for longitudinal observation and reduces follow-up activities for site coordinators by providing visibility into participant engagement. Navio also ensures that individuals can contribute data from home with helpful reminders for important tasks.
Navio Theragnostics Products
Navio provides a suite of applications including a healthcare app for individuals to collect and contribute data, and an admin app to assist in onboarding, tracking participants, and integrating Navio into existing workflows. This platform is designed to be flexible, with customizable interfaces to align with specific branding and messaging needs. Navio's cost-effective solution offers minimal start-up times, low set-up fees, and a pay-for-what-you-use model.
Navio Theragnostics Partners
Navio collaborates with a range of partners including diagnostic labs, pharmaceutical companies, payors, healthcare systems and institutions, advocacy groups, and individual providers. These partnerships help drive research initiatives by providing vital real-world data, contributing to clinical trials, studies, and commercialization efforts. Navio's platform reinforces partner branding and allows for personalized engagements with participants.
Navio Theragnostics Clinical Studies
Navio offers a variety of studies such as the adjuvant chemo side effect study, atezolizumab quality of life study, brain tumor treatment trends, durvalumab quality of life study, nivolumab quality of life study, pembrolizumab quality of life study, and patient perspectives on health and cancer screening. These studies are designed to be easy and convenient for participants, allowing for data collection from the comfort of home.
Navio Theragnostics Compliance and Security
Navio's platform is compliant with HIPAA and GDPR, ensuring that user data is secure and used responsibly. Personal information is only accessible to the user and their care team, with data being anonymized and used only with consent. Employees with access to patient information are trained and certified in HIPAA regulations, reinforcing the commitment to data privacy and security.